טוען...
The effect of food and liquid pH on the integrity of enteric-coated beads from cysteamine bitartrate delayed-release capsules
BACKGROUND: Cysteamine bitartrate delayed-release (DR) capsule (Procysbi(®)) is approved for treatment of nephropathic cystinosis in the USA, Canada, and the EU. The capsules contain cysteamine bitartrate beads that are enteric coated with acid-resistant Eudragit L 30 D-55, preventing drug release i...
שמור ב:
| הוצא לאור ב: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6132578/ https://ncbi.nlm.nih.gov/pubmed/30233142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S174928 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|